Lenz Therapeutics reported strong Q2 results with $5.5 million in revenue, beating estimates by 148%, driven by sales of its presbyopia treatment VIZZ and licensing deals. The company saw a 9% increase in monthly VIZZ packs sold, aided by new TV ads and telehealth options that boosted prescriptions. Despite a loss of $1.02 per share, this was better than expected, signaling improving financial health. Piper Sandler set a $7 price target, suggesting potential stock upside as Lenz expands its commercial launch and partnerships outside the U.S.
Cardano's ADA price fell over 7% to around $0.210, dipping below $0.220 despite large wallets buying 160 million tokens during the decline. Market sentiment is bearish with a low long-to-short ratio of 0.74, though some bullish signs appear in positi...
System1 Group has again rejected Brave Bison's takeover offer, citing that the terms remain unchanged and the offer undervalues System1's shares. Brave Bison's proposal values System1 shares at a discount of 8.2% to the current market price, which Sy...
Bitcoin's price has stalled around $80,000, causing Strategy Inc.'s (MSTR) market value to net asset value (mNAV) premium to shrink near 0.74x, erasing its previous advantage. Strategy holds over 840,000 BTC but faces about $1.5 billion in annual pre...
An analyst initiates coverage of Sezzle with a strong buy rating and a price target of $169 per share, citing key growth drivers such as subscriber growth, increased purchase frequency, new products like SezzleCash and Sezzle Send, enterprise merchan...
The Official TRUMP token fell over 8% within 24 hours to about $2.27 following $3.39 million USDC withdrawals by team-associated wallets using liquidity positions on Solana. Despite this, the token remains up 61% over the past week, rising from aroun...
